Polypeptide in targeted combination with SOX2 protein and application thereof

By targeting and disrupting the interaction domain of the SOX2 protein by a peptide, the problem of chemotherapy resistance in lung squamous cell carcinoma was solved, achieving enhanced efficacy of chemotherapy drugs and safe tumor treatment.

CN121627901APending Publication Date: 2026-03-10GUANGZHOU NAT LAB
3 Cites 0 Cited by

Patent Information

Application Number
CN202411337738.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-09-05
Filing Date
2024-09-23
Publication Date
2026-03-10

AI Technical Summary

Technical Problem

There is a lack of effective methods to reverse chemotherapy resistance in lung squamous cell carcinoma in the current technology, and strategies targeting SOX2 protein have problems such as low tissue specificity, poor biological safety and high cost. Directly inhibiting or degrading SOX2 poses safety risks.

Method used

To develop a peptide that targets and binds to the SOX2 protein, thereby inhibiting its phase separation by recognizing and disrupting the interaction domains of the SOX2 protein and avoiding affecting its transcriptional activation function, and to combine it with a transmembrane peptide to assist in cell entry, for use in the preparation of a drug for adjuvant therapy of squamous cell carcinoma.

Benefits of technology

It effectively reverses tumor chemotherapy resistance, enhances the efficacy of chemotherapy drugs, avoids the impact on the normal function of the organism, and provides a safe and low-cost treatment option.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, and relates to a polypeptide in targeted combination with SOX2 protein and application thereof, the polypeptide has an amino acid sequence as shown in SEQ ID NO.1, or has at least 85%, 90%, 95% or more than 99% of sequence identity with the amino acid sequence; the polypeptide inhibits phase separation of SOX2, liquid drops formed by phase separation of SOX2 can be avoided, then the situation that the liquid drops wrap chemotherapeutic drugs, influence the curative effect of the chemotherapeutic drugs and cause tolerance of tumor cells to the chemotherapeutic drugs is avoided, and the polypeptide does not influence the transcription activation function of SOX2 serving as a transcription factor; the polypeptide can inhibit the phase separation of the SOX2, so that the regulation of normal physiological functions, such as high expression in organs such as eyes of a human body, of the SOX2 as a transcription factor is not influenced, and therefore, the polypeptide disclosed by the invention can reverse chemotherapy drug resistance of tumors such as squamous carcinoma by inhibiting the phase separation of the SOX2, can be used for adjuvant therapy of the tumors such as squamous carcinoma, and has no obvious toxic or side effect on each organ of an organism.
Need to check novelty before this filing date? Find Prior Art